173 related articles for article (PubMed ID: 32620855)
1. Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B.
Shen E; Zhu K; Li D; Pan Z; Luo Y; Bian Q; He L; Song X; Zhen Y; Jin D; Tao L
Commun Biol; 2020 Jul; 3(1):347. PubMed ID: 32620855
[TBL] [Abstract][Full Text] [Related]
2. Comparative genomics of
Janezic S; Dingle K; Alvin J; Accetto T; Didelot X; Crook DW; Lacy DB; Rupnik M
Microb Genom; 2020 Oct; 6(10):. PubMed ID: 33030421
[No Abstract] [Full Text] [Related]
3. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
4. Development and clinical application of a rapid, visually interpretable polymerase spiral reaction for tcdB gene of Clostridioides difficile in fecal cultures.
Yin C; Song Z; Wang X; Li H; Liu Y; Wang Q; Feng X; Song X
FEMS Microbiol Lett; 2023 Jan; 370():. PubMed ID: 37537148
[TBL] [Abstract][Full Text] [Related]
5. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
Wang S; Zhu D; Sun X
Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
[TBL] [Abstract][Full Text] [Related]
6. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain.
Kuehne SA; Collery MM; Kelly ML; Cartman ST; Cockayne A; Minton NP
J Infect Dis; 2014 Jan; 209(1):83-6. PubMed ID: 23935202
[TBL] [Abstract][Full Text] [Related]
7. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
8. A Streamlined Method to Obtain Biologically Active TcdA and TcdB Toxins from
Sapa D; Brosse A; Coullon H; Péan de Ponfilly G; Candela T; Le Monnier A
Toxins (Basel); 2024 Jan; 16(1):. PubMed ID: 38251254
[TBL] [Abstract][Full Text] [Related]
9. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
[TBL] [Abstract][Full Text] [Related]
10. Adenosine receptors differentially mediate enteric glial cell death induced by
Costa DVS; Shin JH; Goldbeck SM; Bolick DT; Mesquita FS; Loureiro AV; Rodrigues-Jesus MJ; Brito GAC; Warren CA
Front Immunol; 2022; 13():956326. PubMed ID: 36726986
[TBL] [Abstract][Full Text] [Related]
11. Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity of
Fettucciari K; Spaterna A; Marconi P; Bassotti G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256032
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
[TBL] [Abstract][Full Text] [Related]
13. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.
Lin Q; Pollock NR; Banz A; Lantz A; Xu H; Gu L; Gerding DN; Garey KW; Gonzales-Luna AJ; Zhao M; Song L; Duffy DC; Kelly CP; Chen X
Clin Infect Dis; 2020 Jun; 70(12):2628-2633. PubMed ID: 31400280
[TBL] [Abstract][Full Text] [Related]
14. Identification of a hemorrhagic determinant in
Zheng Y; Yang Q; Luo J; Zhang Y; Li X; He L; Ma C; Tao L
Microbiol Spectr; 2024 Jun; 12(6):e0035424. PubMed ID: 38709085
[No Abstract] [Full Text] [Related]
15. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
[No Abstract] [Full Text] [Related]
16. Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.
Di Bella S; Ascenzi P; Siarakas S; Petrosillo N; di Masi A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153087
[TBL] [Abstract][Full Text] [Related]
17. The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis.
Bilverstone TW; Garland M; Cave RJ; Kelly ML; Tholen M; Bouley DM; Kaye P; Minton NP; Bogyo M; Kuehne SA; Melnyk RA
PLoS Pathog; 2020 Sep; 16(9):e1008852. PubMed ID: 32960931
[TBL] [Abstract][Full Text] [Related]
18. Increased intestinal permeability and downregulation of absorptive ion transporters
Peritore-Galve FC; Kaji I; Smith A; Walker LM; Shupe JA; Washington MK; Algood HMS; Dudeja PK; Goldenring JR; Lacy DB
Gut Microbes; 2023; 15(1):2225841. PubMed ID: 37350393
[TBL] [Abstract][Full Text] [Related]
19. C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation.
Manion J; Musser MA; Kuziel GA; Liu M; Shepherd A; Wang S; Lee PG; Zhao L; Zhang J; Marreddy RKR; Goldsmith JD; Yuan K; Hurdle JG; Gerhard R; Jin R; Rakoff-Nahoum S; Rao M; Dong M
Nature; 2023 Oct; 622(7983):611-618. PubMed ID: 37699522
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia.
Muñoz M; Restrepo-Montoya D; Kumar N; Iraola G; Camargo M; Díaz-Arévalo D; Roa-Molina NS; Tellez MA; Herrera G; Ríos-Chaparro DI; Birchenall C; Pinilla D; Pardo-Oviedo JM; Rodríguez-Leguizamón G; Josa DF; Lawley TD; Patarroyo MA; Ramírez JD
Sci Rep; 2019 Aug; 9(1):11293. PubMed ID: 31383872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
